Proactive research analyst Robin Davison speaks to Thomas Warner about the report he has written about commercial-stage specialty pharmaceutical company Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF).
Davison's report comes after Shield Therapeutics announced the results of a fundraise as well as a multi-year deal to co-commercialise its Accrufer iron therapy with Viatris Inc in the US.